Department of Biology, Harvey Mudd College, Claremont, California, United States of America.
School of Applied Life Sciences, Keck Graduate Institute, Claremont, California, United States of America.
PLoS Negl Trop Dis. 2020 Mar 13;14(3):e0007790. doi: 10.1371/journal.pntd.0007790. eCollection 2020 Mar.
Trypanosoma brucei are unicellular parasites endemic to Sub-Saharan Africa that cause fatal disease in humans and animals. Infection with these parasites is caused by the bite of the tsetse fly vector, and parasites living extracellularly in the blood of infected animals evade the host immune system through antigenic variation. Existing drugs for Human and Animal African Trypanosomiasis are difficult to administer and can have serious side effects. Resistance to some drugs is also increasing, creating an urgent need for alternative trypanosomiasis therapeutics. We screened a library of 1,585 U.S. or foreign-approved drugs and identified 154 compounds that inhibit trypanosome growth. As all of these compounds have already undergone testing for human toxicity, they represent good candidates for repurposing as trypanosome therapeutics. In addition to identifying drugs that inhibit trypanosome growth, we wished to identify small molecules that can induce bloodstream form parasites to differentiate into forms adapted for the insect vector. These insect stage parasites lack the immune evasion mechanisms prevalent in bloodstream forms, making them vulnerable to the host immune system. To identify drugs that increase transcript levels of an invariant, insect-stage specific surface protein called procyclin, we engineered bloodstream reporter parasites that express Green Fluorescent Protein (GFP) following induction or stabilization of the procyclin transcript. Using these bloodstream reporter strains in combination with automated flow cytometry, we identified eflornithine, spironolactone, and phenothiazine as small molecules that increase abundance of procyclin transcript. Both eflornithine and spironolactone also affect transcript levels for a subset of differentiation associated genes. While we failed to identify compounds that increase levels of procyclin protein on the cell surface, this study is proof of principle that these fluorescent reporter parasites represent a useful tool for future small molecule or genetic screens aimed at identifying molecules or processes that initiate remodeling of the parasite surface during life cycle stage transitions.
布氏锥虫是内生于撒哈拉以南非洲的单细胞寄生虫,会在人类和动物体内引发致命疾病。这些寄生虫通过采采蝇的叮咬感染,而在感染动物血液中游离的寄生虫则通过抗原变异来逃避宿主免疫系统。现有的抗人体和动物非洲锥虫病药物难以施用,且可能具有严重的副作用。一些药物的耐药性也在增加,因此迫切需要替代的锥虫病治疗方法。我们筛选了一个包含 1585 种美国或国外批准的药物的文库,发现了 154 种抑制锥虫生长的化合物。由于所有这些化合物都已经过了人类毒性测试,因此它们是作为锥虫治疗药物重新利用的良好候选物。除了确定抑制锥虫生长的药物外,我们还希望找到能诱导血液期寄生虫分化为适应昆虫媒介的形式的小分子。这些昆虫期寄生虫缺乏在血液期流行的免疫逃避机制,使它们易受宿主免疫系统的影响。为了确定能增加称为前鞭毛蛋白的不变、昆虫阶段特异性表面蛋白的转录本水平的小分子,我们设计了能在诱导或稳定前鞭毛蛋白转录本后表达绿色荧光蛋白 (GFP) 的血液期报告寄生虫。我们使用这些血液期报告株与自动化流式细胞术相结合,鉴定出依氟鸟氨酸、螺内酯和吩噻嗪作为能增加前鞭毛蛋白转录本丰度的小分子。依氟鸟氨酸和螺内酯也会影响一组分化相关基因的转录本水平。虽然我们未能鉴定出能增加细胞表面前鞭毛蛋白水平的化合物,但这项研究证明了这些荧光报告寄生虫是一种有用的工具,可用于未来的小分子或遗传筛选,以鉴定在生命周期阶段转变过程中启动寄生虫表面重塑的分子或过程。